TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06628622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06599723
Drug: Conventional lumbar steroid injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive conventional lumbar steroid injections.
Study: NCT06194448
Drug: Radiation
Normalized name: Miaderm Radiation Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%
Study: NCT05493163
Drug: Thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
Study: NCT05493163
Drug: Standard anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation therapy of acute pulmonary embolism.
Study: NCT04818398
Drug: DS-6016a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
Study: NCT04818398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
Study: NCT04298151
Drug: Zirconomer Improved
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
Study: NCT04298151
Drug: Ketac Molar quick Aplicap
Normalized name: Cal-Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: highly viscous glass ionomer with improved mechanical properties than the conventional GI
Study: NCT05948072
Drug: mFOLFOX 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT05032066
Drug: HZN-825
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Study: NCT05032066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Study: NCT06050915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered as a single dose IV infusion or subcutaneous injection
Study: NCT06050915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
Study: NCT05627154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A lactose-based tablet.
Study: NCT05276401
Drug: 5% Bisphosphocin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT05276401
Drug: Placebo Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT05276401
Drug: 10% Bisphosphocin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT05963217
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
Study: NCT06596876
Drug: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
Study: NCT06596876
Drug: Sustained-release Carbidopa/Levodopa; HRG2010 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
Study: NCT04705584
Drug: Prednisolone (as Acetate)
Normalized name: prednisolone (as acetate)
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
Study: NCT06022588
Drug: U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
Study: NCT06072170
Drug: Kratom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration thirty minutes after the start of a high-fat breakfast
Study: NCT06072170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration thirty minutes after the start of a high-fat breakfast
Study: NCT04582916
Drug: 11CPS13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected IV followed by PET scanning
Study: NCT05691153
Drug: ThisCART19A with Dose Level 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
Study: NCT05691153
Drug: ThisCART19A with Dose Level 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
Study: NCT06249113
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% continous intravenous on tumor craniotomy surgery
Study: NCT04823091
Drug: Fludarabine + Cyclophosphamide + CAR7-T Cells
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
Study: NCT06555640
Drug: DR10624 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DR10624 injection
Study: NCT06555640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: placebo
Study: NCT06173531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given TID, identical in appearance respective to carbetocin treatment
Study: NCT04918173
Drug: Atenativ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin concentrate
Study: NCT05230771
Drug: Chemotheraoy along
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive only the prescribed chemotherapy.
Study: NCT05628311
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 administered subcutaneously (SC) once a week.
Study: NCT06520904
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 inhibitors combined with moderate-intensity statin therapy
Study: NCT05902000
Drug: Intraoperative Drug Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
Study: NCT05633810
Drug: Aspirin Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-enteric-coated tablet taken twice daily.
Study: NCT06597006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study: NCT04775459
Drug: Surfactant administration until 2020
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
Study: NCT04775459
Drug: Surfactant administration since 2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
Study: NCT06404463
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
Study: NCT06404463
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
Study: NCT06237231
Drug: DIT112
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIT112 tablet
Study: NCT06237231
Drug: DIT112 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIT112 placebo tablet
Study: NCT05034874
Drug: IXT-m200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
Study: NCT05069974
Drug: Benzathine Penicilllin G
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
Study: NCT04994106
Drug: AZD5462
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
Study: NCT05283954
Drug: Combination regimen: Fluoxetine, Prednisolone, Ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days.
Study: NCT04978779
Drug: VIP152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV infusion for 28 day cycles.
Study: NCT04978779
Drug: BTKi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken per local prescribing information
Study: NCT04710329
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
Study: NCT05623592
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 17,5/15/10 mg Methotrexate subcutaneously
Study: NCT05269290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once a day on top of standard therapy.
Study: NCT05509023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of Placebo
Study: NCT05054725
Drug: RMC-4630
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-4630 administered orally as a capsule
Study: NCT00002033
Drug: AS-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04991298
Drug: Oral premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anesthesia premedication for congenital Cardiac surgery
Study: NCT05719467
Drug: Buscopan 20 MG/ML Injectable Solution
Normalized name: Buscopan 20 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL intravenously
Study: NCT05719467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g orally
Study: NCT05719467
Drug: Nacl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL intravenously
Study: NCT05428696
Drug: ALXN2080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-in-capsule
Study: NCT05428696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-in-capsule
Study: NCT00002147
Drug: Doxorubicin hydrochloride (liposomal)
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05395416
Drug: HEC74647PA+HEC110114
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily for 12 weeks
Study: NCT05395416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily for 12 weeks
Study: NCT05624424
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
Study: NCT05624424
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study: NCT04492436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
Study: NCT05187715
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg OD
Study: NCT04971512
Drug: Placebo (Part 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EDP-721 (Part 2)
Study: NCT04971512
Drug: Placebo (Part 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EDP-514
Study: NCT00001058
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06408519
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen pills 3x/day
Study: NCT06139133
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06561542
Drug: LX22001 for Injeciton
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
Study: NCT05763550
Drug: HSK16149 20mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
Study: NCT05763550
Drug: HSK16149 40mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
Study: NCT04920695
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulmonary vasodilator (gas).
Study: NCT04920695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical grade normoxic gas (FiO2 = 0.21)
Study: NCT05174754
Drug: Best Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy with biologic agent or small-molecule therapy
Study: NCT06291207
Drug: AD-224A
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06291207
Drug: AD-224B
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06291207
Drug: AD-224C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06291207
Drug: Placebo of AD-224A
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06291207
Drug: Placebo of AD-224B
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06291207
Drug: Placebo of AD-224C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06536400
Drug: HSK42360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, QD
Study: NCT05239169
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
Study: NCT04881123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
Study: NCT04701216
Drug: SHR8735
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
Study: NCT05109104
Drug: CAP UnScented
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05109104
Drug: CAP Herbal Mint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05109104
Drug: CAP Mountain Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05109104
Drug: SPF Standard Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Study: NCT04853875
Drug: Tetracycline, Metronidazole, Bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
Study: NCT04965766
Drug: U3-1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.
Study: NCT04853875
Drug: Amoxicillin, Metronidazole, Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
Study: NCT06348888
Drug: BAY2927088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04848688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
Study: NCT05264896
Drug: 5-FU, Leucovorin, Oxaliplatin, Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT 4 cycles pre and post radical gastrectomy
Study: NCT05264896
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX 8 cycles post radical gastrectomy
Study: NCT06089395
Drug: Jiajian Guishen granules
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Guiaphen HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
Study: NCT01172249
Drug: Glucosamine sulfate + chondroitin sulfate - MANTECORP
Normalized name: chondroitin sulfates / glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
Study: NCT01172249
Drug: Glucosamine sulfate + chondroitin sulfate - CONDROFLEX
Normalized name: chondroitin sulfates / glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
Study: NCT05526703
Drug: D064, D701, placebo of D012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
Study: NCT05526703
Drug: D012, placebo of D064, placebo of D701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
Study: NCT06557603
Drug: Soolantra ® (Ivermectin) cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
Study: NCT05533892
Drug: Nocardia rubra cell wall skeleton
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)
Study: NCT06392126
Drug: nL-CHCHD-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antisense oligonucleotide
Study: NCT04968951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT00002120
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes